BTTX
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q3 | -0.15 | $0 | -$6M |
| 2023 Q2 | -0.24 | $0 | -$6M |
| 2023 Q1 | -0.39 | $0 | -$9M |
| 2022 Q4 | -0.37 | $0 | -$7M |
| 2022 Q3 | -0.48 | $0 | -$7M |
| 2022 Q2 | -0.42 | $0 | -$7M |
| 2022 Q1 | -0.43 | $0 | -$9M |
| 2021 Q4 | -0.71 | $284,000 | -$30M |